E-submission
Articles
- Page Path
- HOME > J Pathol Transl Med > Volume 40(2); 2006 > Article
- Original Article Immunohistochemical Expression of the Sodium/Iodide Symporter in Patients with Primary Lung Cancer.
- Hyoun Wook Lee, Do Young Kang, Phil Jo Choi, Doo Kyung Yang, Ki Nam Kim, Kyung Eun Lee, Mee Sook Roh
-
Journal of Pathology and Translational Medicine 2006;40(2):81-85
DOI: https://doi.org/
2Department of Nuclear Medicine, Dong-A University College of Medicine, Busan, Korea.
3Department of Thoracic and Cardiovascular Surgery, Dong-A University College of Medicine, Busan, Korea.
4Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
5Department of Diagnostic Radiology, Dong-A University College of Medicine, Busan, Korea.
6Medical Research Center for Cancer Molecular Therapy, Dong-A University College of Medicine, Busan, Korea.
- 1,745 Views
- 16 Download
- 0 Crossref
- 0 Scopus
Abstract
BACKGROUND
The sodium/iodide symporter (NIS) is a membrane glycoprotein that facilitates the uptake of iodine by thyroid follicular cells. Although the use of radioiodide is essential for the diagnosis and treatment of thyroid diseases, few studies have been conducted to investigate the use of NIS-mediated radioiodide accumulation in lung cancer.
We evaluated the expression of NIS by immunohistochemistry in order to examine the diagnostic or therapeutic feasibility of using radioiodide in the treatment of primary lung cancer.
METHODS
Immunohistochemistry for NIS was performed in 139 lung cancers. The expression pattern of NIS was compared with the clinicopathological characteristics of the tumors.
RESULTS
NIS immunoreactivity was detected in 75 (54.0%) of the 139 cases. Twenty-three (37.7%) of the 61 squamous cell carcinomas, 49 (76.6%) of the 64 adenocarcinomas, 2 (40.0%) of the 5 small cell carcinomas, and 3 (33.3%) of the 9 other carcinomas showed positive NIS immunoreactivity. The expression of NIS was significantly associated with the histologic type (p<0.001), but it did not correlate with tumor size, lymphovascular invasion or lymph node metastasis.
CONCLUSIONS
The presence of NIS was detected in lung cancer tissue using immunohistochemistry. Lung cancer potentially could be targeted with radioiodide for both diagnosis and treatment, especially in cases of adenocarcinoma.
Cited
